Iovance Biotherapeutics, Inc. Common Stock IOVA

Iovance Biotherapeutics, Inc. es una empresa biofarmacéutica en fase clínica que comercializa terapias con células T autólogas para tratar el cáncer de tumores sólidos. Desarrolla y ofrece terapias con linfocitos infiltrantes de tumores (TIL) para pacientes con cánceres de tumores sólidos. Su principal candidato a producto, lifileucel, se está desarrollando en melanoma avanzado, metastásico o irresecable, así como en otras indicaciones. Lifileucel se está investigando en dos cohortes consecutivas en un ensayo clínico de pacientes con melanoma avanzado después de la terapia anti-PD-1, incluida en una cohorte pivotal definida prospectivamente. Ha iniciado un ensayo clínico de Fase III de lifileucel en combinación con pembrolizumab, TILVANCE-301. La empresa también está siguiendo estrategias de registro para lifileucel en cáncer de cuello uterino avanzado y para su terapia TIL, LN-145, en cáncer de pulmón no microcítico metastásico. Su primera terapia TIL genéticamente modificada, IOV-4001, con PD-1 inactivado, se encuentra en ensayo clínico de Fase I/II, IOV-GM1-201.

• Zacks Investment Research 2 oct

  These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could outperform expectations: Align Technology (ALGN) with a +1.23% ESP ahead of October 28 earnings, and Iovance Biotherapeutics (IOVA) with a +22.22% ESP before November 5 earnings. Both stocks hold a Zacks Rank #3 (Hold) rating, and positive ESP combined with favorable rankings historically produce positive surprises 70% of the time.

  

• GlobeNewswire Inc. 1 oct

  Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

  Iovance Biotherapeutics announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer effective September 30, 2026. Berkowitz brings extensive experience in global drug development and cell therapy from previous roles at Arvinas Pharmaceuticals and Bristol Myers Squibb, where he led clinical strategies resulting in FDA approvals for CAR-T cell therapies and other treatments. He will lead Iovance's TIL platform development across multiple solid tumor cancers.

  

• Zacks Investment Research 30 sept

  IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026

  Iovance Biotherapeutics raised its 2026 revenue outlook to $410-$420 million from $350-$370 million, driven by strong patient demand for its therapies Amtagvi and Proleukin. The stock surged 31.5% following the announcement. Amtagvi, the first FDA-approved TIL therapy for melanoma, generated $151 million in sales in H1 2026 with 54% year-over-year growth, and the company plans to expand authorized treatment centers from 100 to at least 110 by year-end.

  

• Zacks Investment Research 30 sept

  Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

  Iovance Biotherapeutics shares surged 31.5% to $14.45 after the company raised its full-year 2026 revenue guidance to $410-$420 million from $350-$370 million. The stock is expected to report quarterly revenues of $106.85 million (up 58.4% year-over-year) with a loss of $0.12 per share. However, analysts note that without recent earnings estimate revisions, the stock's momentum may not sustain, and the company carries a Zacks Rank #3 (Hold) rating.

  

• Zacks Investment Research 21 sept

  Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

  Biotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.